Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Marinus Pharma CS
(NQ:
MRNS
)
1.420
-0.040 (-2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
Next >
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
January 30, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
January 20, 2023
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China
November 17, 2022
Via
Benzinga
BARDA Exercises First Contract Option With Marinus Pharma For Its Epilepsy Candidate
September 22, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
Via
Benzinga
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
January 05, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
November 30, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Week In Review: Fosun Signs $840 Million Deal For US Rights To Henlius' PD-1
November 19, 2022
Fosun Pharma announced it has licensed US rights to a PD-1 candidate from Henlius Biotech in an $840 million agreement. Meanwhile, Tenacia Biotechnology in-licensed greater China rights to a seizure...
Via
Talk Markets
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board
November 17, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
November 17, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
November 09, 2022
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Via
Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
November 08, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast...
Via
Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
November 08, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 08, 2022
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 08, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
Via
Benzinga
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
November 07, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Proposed Public Offering
November 07, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners
October 31, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022
October 25, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
7 Sizzling Stocks That Are Oblivious to the Manic Market
October 20, 2022
While some stocks to buy have performed surprisingly well recently, they remain relatively obscure, providing a contrarian opportunity.
Via
InvestorPlace
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
October 11, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
September 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
September 07, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Looking Into Marinus Pharmaceuticals's Return On Capital Employed
September 06, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) brought in sales totaling $1.79 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 103.67%, resulting in a loss of $39.43...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.